Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis Patients

Starting soon · Phase 4

Conditions studied: Renal Anemia

In brief

This is a two-period, two-sequence crossover study in patients receiving maintenance peritoneal dialysis. All participants remain on background darbepoetin alfa therapy throughout the study. The study compares add-on vadadustat plus background darbepoetin alfa with background darbepoetin alfa alone, with each treatment period lasting 8 weeks and separated by a 4-week washout period. Monthly laboratory assessments and dialysis adequacy measurements will be performed to evaluate anemia control, quality of life, inflammation, and dialysis adequacy.

Key facts

Study ID

NCT07537816

Run by

Mackay Memorial Hospital

People needed

40

Starts

2026-04-15

Expected to finish

2026-10-15

Last updated by the study team

2026-04-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older
• Receiving maintenance peritoneal dialysis
• Followed at the outpatient clinics of MacKay Memorial Hospital
• Receiving background darbepoetin alfa therapy
• Able and willing to provide informed consent

You may not qualify if…

• Blood pressure >170/80 mmHg on three separate occasions
• Recent cardiovascular events within the past 3 months, including coronary artery disease, myocardial ischemia, cerebrovascular disease, or peripheral artery disease
• Gastrointestinal bleeding within the past 3 months
• Active malignancy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.